Nvidia invests in Generate Biomedicines as CEO Jensen Huang highlights AI’s transformative role in life sciences and drug research.
Nvidia disclosed a stake in biotech company Generate Biomedicines (GENB) in a May financial filing, marking a shift toward healthcare investments. The move aligns with CEO Jensen Huang’s view that AI’s most significant impact will be in life sciences, not just tech sectors like cloud computing or telecommunications.
The investment follows Nvidia’s January announcement of a $1 billion AI co-innovation lab with Eli Lilly, aimed at accelerating drug discovery. Huang emphasized AI’s potential to revolutionize healthcare, combining Nvidia’s AI expertise with Eli Lilly’s medical research capabilities.
Generate Biomedicines focuses on AI-driven drug development, fitting Nvidia’s strategy to expand beyond chip manufacturing into high-growth sectors leveraging artificial intelligence.